Correlation Between Processa Pharmaceuticals and Spero Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Processa Pharmaceuticals and Spero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Processa Pharmaceuticals and Spero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Processa Pharmaceuticals and Spero Therapeutics, you can compare the effects of market volatilities on Processa Pharmaceuticals and Spero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Processa Pharmaceuticals with a short position of Spero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Processa Pharmaceuticals and Spero Therapeutics.

Diversification Opportunities for Processa Pharmaceuticals and Spero Therapeutics

0.59
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Processa and Spero is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Processa Pharmaceuticals and Spero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spero Therapeutics and Processa Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Processa Pharmaceuticals are associated (or correlated) with Spero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spero Therapeutics has no effect on the direction of Processa Pharmaceuticals i.e., Processa Pharmaceuticals and Spero Therapeutics go up and down completely randomly.

Pair Corralation between Processa Pharmaceuticals and Spero Therapeutics

Given the investment horizon of 90 days Processa Pharmaceuticals is expected to generate 4.31 times more return on investment than Spero Therapeutics. However, Processa Pharmaceuticals is 4.31 times more volatile than Spero Therapeutics. It trades about 0.08 of its potential returns per unit of risk. Spero Therapeutics is currently generating about -0.15 per unit of risk. If you would invest  98.00  in Processa Pharmaceuticals on September 17, 2024 and sell it today you would earn a total of  7.00  from holding Processa Pharmaceuticals or generate 7.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Processa Pharmaceuticals  vs.  Spero Therapeutics

 Performance 
       Timeline  
Processa Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Spero Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Processa Pharmaceuticals and Spero Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Processa Pharmaceuticals and Spero Therapeutics

The main advantage of trading using opposite Processa Pharmaceuticals and Spero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Processa Pharmaceuticals position performs unexpectedly, Spero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will offset losses from the drop in Spero Therapeutics' long position.
The idea behind Processa Pharmaceuticals and Spero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance